natgillin/translations-raw huggingface dataset:
Trydonis forbedrede dyspnø signifikant (målt som transitionalt dyspnøindeks - TDI - fokal score) efter 26 ugers behandling sammenlignet med baseline (med 1,71 enheder, p < 0,001), men den justerede gennemsnitlige forskel versus en fast kombination af beclometasondipropionat og formoterol var ikke statistisk signifikant (0,21 enheder, p = 0,160). 
Trydonis significantly improved dyspnoea (measured as the Transition Dyspnoea Index - TDI - focal score) after 26 weeks of treatment compared with baseline (by 1.71 units; p < 0.001), but the adjusted mean difference versus a fixed combination of beclometasone dipropionate and formoterol was not statistically significant (0.21 units; p = 0.160).
En overdosering af Trydonis kan give tegn og symptomer, der kan skyldes virkningerne af de enkelte komponenter, herunder tegn og symptomer ved overdosering med andre beta2-agonister eller antikolinergika, og som svarer til de kendte klassevirkninger for kortikosteroider (se pkt. 
An overdose of Trydonis may produce signs and symptoms due to the individual component's actions, including those seen with overdose of other beta2-agonists or anticholinergics and consistent with the known inhaled corticosteroid class effects (see section 4.4).
Trydonis skal administreres med forsigtighed hos patienter med aktiv eller latent lungetuberkulose, samt ved svampeinfektioner og virale infektioner i luftvejene. 
Trydonis should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Der blev observeret tilsvarende virkninger, når Trydonis blev sammenlignet med den ekstemporære trippelkombination. 
Similar effects were seen when comparing Trydonis with the extemporary triple combination.
• disulfiram, et lægemiddel, der bruges til at behandle personer med alkoholisme (alkoholproblemer) eller metronidazol, et antibiotikum, der bruges til at behandle infektion i din krop kan forårsage bivirkninger (f.eks. kvalme, opkastning, mavesmerter) på grund af den lille mængde alkohol i Trydonis. 
• Disulfiram, a medicine used in the treatment of people with alcoholism (drinking problems) or metronidazole, an antibiotic to treat infection in your body can cause side effects (e.g. feeling sick, being sick, stomach pain) due to the small amount of alcohol in Trydonis.
Det frarådes at stoppe behandlingen med Trydonis pludseligt. 
It is recommended that treatment with Trydonis should not be stopped abruptly.
Hvis du udvikler en forværring af din stakåndethed eller hvæsende vejrtrækning (vejrtrækningen har en pibende lyd) umiddelbart efter du indånder dit lægemiddel, skal du holde op med at bruge Trydonis-inhalatoren, og du skal øjeblikkeligt bruge din hurtigtvirkende ”lindrende” inhalator. 
If you develop worsening shortness of breath or wheezing (breathing with a whistling sound), straight after inhaling your medicine, stop using Trydonis inhaler and use your quick-acting “reliever” inhaler straightaway.
Trydonis leveres i en trykbeholder (belagt aluminium) med en doseringsventil. 
Trydonis comes in a pressurised container (coated aluminium), with a metering valve.
Trydonis leveres med en dosistæller eller dosisindikator bag på inhalatoren, som viser hvor mange pust, der er tilbage. 
Trydonis is provided with a dose counter or dose indicator on the back of the inhaler, which shows how many actuations are left.
Trydonis bør anvendes med forsigtighed hos patienter med hjertearytmier, især tredjegrads atrioventrikulært blok og takyarytmier (accelereret og/eller uregelmæssigt hjerteslag), idiopatisk subvalvulær aortastenose, hypertrofisk obstruktiv kardiomyopati, svær hjertesygdom (især akut myokardieinfarkt, iskæmisk hjertesygdom, kongestivt hjertesvigt), okklusiv karsygdom (især arteriosklerose), arteriel hypertension og aneurisme. 
Trydonis should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm.
En analyse af patienter, der responderede, viste, at en signifikant større procentdel af patienterne havde en klinisk signifikant forbedring (reduktion versus baseline, der var større end eller lig med 4) efter 26 og 52 uger med Trydonis end med en fast kombination af beclometasondipropionat og formoterol og med tiotropium. 
A responder analysis showed that a significantly greater percentage of patients had a clinically significant improvement (reduction versus baseline of greater than or equal to 4) after 26 and 52 weeks with Trydonis than with a fixed combination of beclometasone dipropionate and formoterol and with tiotropium.
Det skal besluttes, om amning skal ophøre eller behandling med Trydonis seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for mødrene. 
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Trydonis therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mothers.
Studiet sammenlignede data opnået efter behandling med en enkeltdosis Trydonis (4 inhalationer med 100/6/25 mikrogram, en ikke-markedsført formulering, der indeholder to gange den godkendte styrke af glycopyrronium), eller en enkeltdosis af den ekstemporære kombination af beclometasondipropionat/formoterol (4 inhalationer med 100/6 mikrogram) plus glycopyrronium (4 inhalationer med 25 mikrogram). 
The study compared data obtained after treatment with a single dose of Trydonis (4 inhalations of 100/6/25 micrograms, a non-marketed formulation containing twice the approved strength of glycopyrronium) or a single dose of the extemporary combination of beclometasone dipropionate/formoterol (4 inhalations of 100/6 micrograms) plus glycopyrronium (4 inhalations of 25 micrograms).
Hvis du allerede bruger Trydonis 
If you are already using Trydonis
En analyse af patienter, der responderede, viste, at en signifikant større procentdel af patienterne havde en klinisk signifikant forbedring (fokal score større end eller lig med 1) efter 26 uger med Trydonis end med en fast kombination af beclometasondipropionat og formoterol (57,4 % versus 51,8 %; p = 0,027). 
A responder analysis showed that a significantly greater percentage of patients had a clinically significant improvement (focal score greater than or equal to 1) after 26 weeks with Trydonis than with a fixed combination of beclometasone dipropionate and formoterol (57.4% versus 51.8%; p = 0.027).
Sammenlignet med tiotropium forbedrede Trydonis signifikant IC med 39 ml (p = 0,025) og 60 ml (p = 0,001) efter hhv. 26 og 52 ugers behandling. 
Compared with tiotropium, Trydonis significantly improved IC by 39 mL (p = 0.025) and 60 mL (p = 0.001) after 26 and 52 weeks of treatment respectively.
Hvis du holder op med at bruge Trydonis 
If you stop using Trydonis
I et inhalationsstudie af hunde i telemetri var det kardiovaskulære system et større målsystem for Trydonis' akutte virkninger (øget hjertefrekvens, nedsat blodtryk, EKG-ændringer ved større doser), virkninger, der sandsynligvis er relateret til den beta2-adrenerge aktivitet af formoterol, og den antimuskarine aktivitet af glycopyrronium. 
In an inhalation study in telemetered dogs, the cardiovascular system was a major target system for acute effects of Trydonis (increase in heart rate, decrease in blood pressure, ECG changes at higher doses), effects probably mainly related to the beta2-adrenergic activity of formoterol and the anti-muscarinic activity of glycopyrronium.
Der blev ikke observeret nogen forskel ved sammenligning med Trydonis og den ekstemporære trippelkombination bestående af fluticason og vilanterol fast kombination plus tiotropium. 
No differences were observed when comparing Trydonis and the extemporary triple combination made of fluticasone and vilanterol fixed combination plus tiotropium.
I inhalationsstudier af op til 13 ugers varighed med gentagne doser Trydonis af rotter og hunde, var de vigtigste observerede ændringer relateret til virkningen på immunsystemet (sandsynligvis fra de systemiske kortikosteroidvirkninger af beclometasondipropionat, og dens aktive metabolit beclometason-17-monopropionat), og på det kardiovaskulære system (sandsynligvis relateret til den beta2-adrenerge aktivitet af formoterol, og den antimuskarine aktivitet af glycopyrronium). 
In repeat dose inhalation studies with Trydonis in rats and dogs of up to 13 weeks duration, the main observed alterations were related to effects on the immune system (probably due to systemic corticosteroid effects of beclometasone dipropionate and its active metabolite beclometasone17-monopropionate) and on the cardiovascular system (probably related to the beta2-adrenergic activity of formoterol and the anti-muscarinic activity of glycopyrronium).
Hvis du har glemt at bruge Trydonis 
If you forget to use Trydonis
Desuden forlængede Trydonis signifikant tiden til den første eksacerbationer, sammenlignet med både en fast kombination af beclometasondipropionat og formoterol og med tiotropium (hazard ratio hhv. 0,80 og 0,84, p = hhv. 0,020 og 0,015), uden nogen forskelle mellem Trydonis og den ekstemporære trippelkombination bestående af beclometasondipropionat og formoterol fastdosiskombination plus tiotropium (hazard ratio 1,06). 
In addition, compared with both a fixed combination of beclometasone dipropionate and formoterol and with tiotropium, Trydonis significantly prolonged the time to first exacerbation (hazard ratio 0.80 and 0.84 respectively; p = 0.020 and 0.015 respectively), with no differences between Trydonis and the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (hazard ratio 1.06).
5.2) har påvist, at ved sammenligning med rutinemæssig anvendelse uden en spacer-anordning, forlængede anvendelsen af Trydonis med AeroChamber Plus spacer-anordningen den totale systemiske eksponering (AUC0-t) over for glycopyrronium. 
Single dose pharmacokinetic data (see section 5.2) have demonstrated that in comparison to routine use without a spacer device, the use of Trydonis with the AeroChamber Plus spacer device increased the total systemic exposure (AUC0-t) to glycopyrronium.
Trydonis 87 mikrogram/5 mikrogram/9 mikrogram inhalationsspray, opløsning 
Trydonis 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Du skal sammen med lægen beslutte, om amning skal ophøre eller behandling med Trydonis stoppes, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for dig. 
You and your doctor must make a decision whether to discontinue breast-feeding or to discontinue/abstain from Trydonis therapy taking into account the benefit of breast-feeding for your child and the benefit of therapy for you.
Hos patienter med svært nedsat nyrefunktion, herunder med nyresygdom i slutstadiet, der kræver dialyse, især hvis det er forbundet med en signifikant reduktion af legemsvægten, bør Trydonis kun anvendes, hvis den forventede fordel opvejer den mulige risiko (se pkt. 
In patients with severe renal impairment, including those with end-stage renal disease requiring dialysis, especially if associated with a significant body weight reduction, Trydonis should be used only if the expected benefit outweighs the potential risk (see section 5.2).
For en sikkerheds skyld bør Trydonis derfor undgås under graviditeten og fødsel. 
Therefore, as a precautionary measure, it is preferable to avoid the use of Trydonis during pregnancy and during labour.
Du må ikke anvende Trydonis under amning. 
You should not use Trydonis during breast-feeding.
Der blev ikke observeret nogen forskelle ved sammenligning af Trydonis og den ekstemporære trippelkombination bestående af en fastdosiskombination af beclometasondipropionat og formoterol plus tiotropium (forskel på 3 ml i FEV1 før dosering efter 52 ugers behandling). 
No differences were observed when comparing Trydonis and the extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol plus tiotropium (difference of 3 mL in pre-dose FEV1 after 52 weeks of treatment).
Der blev ikke observeret nogen forskelle, når Trydonis blev sammenlignet med den ekstemporære trippelkombination bestående af beclometasondipropionat og formoterol fastdosiskombination plus tiopropium (hyppigheden af moderate/svære eksacerbationer: 0,46 versus 0,45 hændelser pr. patient/år). 
No differences were observed when comparing Trydonis with the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (moderate/severe exacerbation rate: 0.46 versus 0.45 events per patient/year).
Sammenlignet med en fastdosiskombination af indacaterol og glycopyrronium forbedrede Trydonis den gennemsnitlige FEV1 inden dosering i løbet af den 52-ugers behandlingsperiode med 22 ml (p = 0,018). 
Compared with a fixed combination of indacaterol and glycopyrronium, Trydonis improved average pre-dose FEV1 over the 52-week treatment period by 22 mL (p=0.018).
Trydonis er en inhalationsspray, opløsning. 
Trydonis is a pressurised inhalation, solution.
TRIBUTE var et 52-ugers aktivt kontrolleret studie, der sammenlignede Trydonis med en fastdosiskombination af indacaterol/glycopyrronium 85/43 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (1.532 randomiserede patienter). 
TRIBUTE was a 52-week activecontrolled study comparing Trydonis with a fixed combination of indacaterol/glycopyrronium 85/43 micrograms inhalation powder, hard capsule, one inhalation once daily (1,532 randomised patients).
TRILOGY-studiet sammenlignede Trydonis med en fastdosiskombination af beclometasondipropionat og formoterol 100/6 mikrogram givet som to inhalationer to gange dagligt (1.368 randomiserede patienter). 
Study TRILOGY compared Trydonis with a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily (1,368 randomised patients).
Hos patienter med svært nedsat leverfunktion må Trydonis kun anvendes, hvis den forventede fordel opvejer den mulige risiko (se pkt. 
In patients with severe hepatic impairment, Trydonis should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Anvendelsen af Trydonis til patienter med svært nedsat nyrefunktion eller nyresygdom i slutstadiet der kræver dialyse, især hvis det er forbundet med en signifikant vægttab, bør kun overvejes, hvis den forventede fordel opvejer den mulige risiko (se pkt. 
Use of Trydonis in patients with severe renal impairment or end-stage renal disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see section 4.4 and section 5.2).
Sammenlignet med tiotropium forbedrede Trydonis FEV1 før dosering med 51 ml efter 26 ugers behandling og med 61 ml efter 52 ugers behandling. 
Compared with tiotropium, Trydonis improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment.
TRISTAR var et 26-ugers, åbent, aktivt kontrolleret studie, der sammenlignede Trydonis med en ekstemporær kombination bestående af en fastdosiskombination af fluticason/vilanterol 92/22 mikrogram inhalationspulver, en inhalation én gang dagligt plus tiotropium 18 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (1.157 randomiserede patienter). 
TRISTAR was a 26-week active-controlled open label study comparing Trydonis with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients).
Brug af anden medicin sammen med Trydonis 
Other medicines and Trydonis
Sådan skal du bruge Trydonis 
How to use Trydonis
Desuden bør en langvarig administration af Trydonis sammen med andre lægemidler, der indeholder antikolinergika, ikke anvendes, på grund af den antikolinerge virkning af glycopyrronium (se pkt. 
Additionally, due to the anticholinergic effect of glycopyrronium, the long-term co-administration of Trydonis with other anticholinergic-containing medicinal products is not recommended (see section 4.5).
Sammenlignet med en fastdosiskombination af indacaterol og glycopyrronium nedsatte Trydonis hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 15 % (hyppighed: 0,50 versus 0,59 hændelser pr. patient/år, p = 0,043). 
Compared with a fixed combination of indacaterol and glycopyrronium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043).
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Trydonis FEV1 2-timer efter dosering med 117 ml efter 26 ugers behandling, og med 103 ml efter 52 ugers behandling (p < 0,001). 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001).
Trydonis 87/5/9 mikrogram inhalationsspray beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium Til inhalation 
Trydonis 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use
Sammenlignet med tiotropium nedsatte Trydonis hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 20 % (hyppighed: 0,46 versus 0,57 hændelser pr. patient/år, p = 0,003). 
Compared with tiotropium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003).
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Trydonis FEV1 før dosering med 81 ml efter 26 ugers behandling og med 63 ml efter 52 ugers behandling. 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment.
Indlægsseddel: Information til brugeren Trydonis 87 mikrogram/5 mikrogram/9 mikrogram inhalationsspray, opløsning beclometasondipropionat/formoterolfumaratdihydrat/glycopyrronium (beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium) 
Package leaflet: Information for the user Trydonis 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Trydonis 87/5/9 mikrogram inhalationsspray, opløsning beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium 
Trydonis 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Sammenlignet med en fastdosiskombination af beclometasondipropionat og formoterol nedsatte Trydonis hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 23 % (hyppighed: 0,41 versus 0,53 hændelser pr. patient/år, p = 0,005). 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005).
Den daglige dosis af Trydonis svarer til en medium dosis af inhaleret kortikosteroid. 
The daily dose of Trydonis corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids.
moderate eksacerbationer) med 32 % (hyppighed: 0,067 versus 0,098 hændelser pr. patient/år, p = 0,017). 
Compared with tiotropium, Trydonis also reduced the rate of severe exacerbations (i.e. excluding moderate exacerbations) by 32% (rate: 0.067 versus 0.098 events per patient/year; p = 0.017).
Desuden blev virkningerne sammenlignet med en ekstemporær trippelkombination, der bestod af en fast kombination af to inhalationer af beclometasondipropionat og formoterol 100/6 mikrogram to gange dagligt plus tiotropium 18 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (2.691 randomiserede patienter). 
Study TRINITY compared Trydonis with tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily; in addition, effects were compared with an extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (2,691 randomised patients).
Det skal du vide, før du begynder at bruge Trydonis Sådan skal du bruge Trydonis Bivirkninger 
What Trydonis is and what it is used for What you need to know before you use Trydonis How to use Trydonis
Udseende og pakningsstørrelser 
What Trydonis looks like and contents of the pack
De kan være tegn på lungebetændelse (kan forekomme hos op til 1 ud af 10 personer): 
Tell your doctor if you have any of the following while using Trydonis as they could be symptoms of a lung infection (may affect up to 1 in 10 people):
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Matever den 03. oktober 2011. 
The European Commission granted a marketing authorisation valid throughout the European Union for Matever on 03 October 2011.
Andre oplysninger om Matever 
Other information about Matever
Den fuldstændige EPAR for Matever findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
The full EPAR for Matever can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Sekundær generalisering forekommer, når denne overaktivitet senere breder sig til hele hjernen. 
Secondary generalisation occurs when the overactivity later reaches the whole brain.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Matever. 
This is a summary of the European public assessment report (EPAR) for Matever.
Det er stadig uklart, hvordan levetiracetam præcis virker, men det synes at gribe ind i funktionen af et protein kaldet synaptisk vesikelprotein 2A, som findes i mellemrummene mellem nerverne og er involveret i frigivelsen af kemiske signalstoffer fra nervecellerne. 
The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells.
Det er en form for epilepsi, hvor en for stærk elektrisk aktivitet i den ene side af hjernen medfører symptomer som pludselige stødvise bevægelser af en del af kroppen, forvrænget hørelse, lugtesans eller syn, følelsesløshed eller pludselig angst. 
This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear.
Matever er et "generisk lægemiddel". 
Matever is a ‘generic medicine'.
Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om, hvordan Matever skal anvendes. 
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Matever.
Matever tabletter synkes med væske. 
Matever tablets are swallowed with liquid.
Det er med til at bevirke, at Matever kan stabilisere den elektriske aktivitet i hjernen og forhindre anfald. 
This helps Matever to stabilise electrical activity in the brain and prevent seizures.